tirzepatide summit trial In pts wiht HFpEF and obesity, (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in https://t.co/8ZHm4gySiL summit trial tirzepatide results SUMMIT:

doi: 10.1053/j.gastro.2011.05.032 59 IwamotoMKojiTMakiyamaKKobayashiNNakanePK

Because of the potent pharmacological actions and potential drug interactions associated with berberine and ALA, it is imperative that you work closely with a knowledgeable healthcare provider to determine if this combination is safe and appropriate for your specific clinical picture

A-lipoic acid

Therefore, we reviewed available literature describing the versatile effects of SGLT-2i on CNS, with the aim of establishing the actual role played by SNS and central physiology of SGLT-2i with regards to the mechanism of cardiovascular benefits